{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:15:23Z","timestamp":1778087723524,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:00:00Z","timestamp":1760227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001317","name":"Swansea University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000381","name":"Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jval.2025.09.3063","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:55:15Z","timestamp":1760536515000},"page":"476-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Responsiveness of Preference-Based Health-Related Quality of Life, Social Care, and Well-Being Measures in the Context of Multiple Sclerosis"],"prefix":"10.1016","volume":"29","author":[{"given":"Elizabeth","family":"Goodwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Heather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nia","family":"Morrish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Boddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Chataway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rod","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Hawton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jval.2025.09.3063_bib1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/hec.3086","article-title":"The influence of cost-effectiveness and other factors on NICE decisions","volume":"24","author":"Dakin","year":"2015","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2025.09.3063_bib2","series-title":"Measuring and Valuing Health Benefits for Economic Evaluation","author":"Brazier","year":"2016"},{"issue":"10","key":"10.1016\/j.jval.2025.09.3063_bib3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jval.2025.09.3063_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/jnnp.2003.017897","article-title":"A comparison of health utility measures for the evaluation of multiple sclerosis treatments","volume":"76","author":"Fisk","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.jval.2025.09.3063_bib5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jval.2016.01.002","article-title":"Health utilities for multiple sclerosis","volume":"19","author":"Hawton","year":"2016","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2025.09.3063_bib6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/1352458520954172","article-title":"Measuring the cost-effectiveness of treatments for people with multiple sclerosis: beyond quality-adjusted life-years","volume":"28","author":"Hawton","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.jval.2025.09.3063_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c1786","article-title":"Continuing the multiple sclerosis risk sharing scheme is unjustified","volume":"340","author":"McCabe","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2025.09.3063_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/CEOR.S4225","article-title":"Assessing cost-effectiveness in the management of multiple sclerosis","volume":"1","author":"Phillips","year":"2009","journal-title":"Clinicoecon Outcomes Res"},{"issue":"13","key":"10.1016\/j.jval.2025.09.3063_bib9","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2165\/11538000-000000000-00000","article-title":"Pharmacoeconomic considerations in the treatment of multiple sclerosis","volume":"70","author":"Sharac","year":"2010","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.jval.2025.09.3063_bib10","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0895-4356(01)00407-3","article-title":"A taxonomy for responsiveness","volume":"54","author":"Beaton","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jval.2025.09.3063_bib11","series-title":"Beta Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis","year":"2002"},{"key":"10.1016\/j.jval.2025.09.3063_bib12","series-title":"Natalizumab for the Treatment of Adults With Highly Active Relapsing-Remitting Multiple Sclerosis","year":"2007"},{"key":"10.1016\/j.jval.2025.09.3063_bib13","series-title":"Fingolimod for the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis","year":"2012"},{"issue":"6","key":"10.1016\/j.jval.2025.09.3063_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40258-015-0194-1","article-title":"Improving cross-sector comparisons: going beyond the health-related QALY","volume":"13","author":"Brazier","year":"2015","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2025.09.3063_bib15","series-title":"Developing NICE Guidelines: the Manual (PMG20). NICE Process and Methods","year":"2024"},{"issue":"11","key":"10.1016\/j.jval.2025.09.3063_bib16","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"12","key":"10.1016\/j.jval.2025.09.3063_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13120","article-title":"Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods","volume":"13","author":"Hobart","year":"2009","journal-title":"Health Technol Assess"},{"issue":"8","key":"10.1016\/j.jval.2025.09.3063_bib18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jval.2015.07.002","article-title":"A quality-adjusted life-year measure for multiple sclerosis: developing a patient-reported health state classification system for a multiple sclerosis-specific preference-based measure","volume":"18","author":"Goodwin","year":"2015","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2025.09.3063_bib19","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jval.2015.10.004","article-title":"Estimating a preference-based index for an eight-dimensional health state classification system for multiple sclerosis","volume":"18","author":"Goodwin","year":"2015","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2025.09.3063_bib20","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jval.2018.03.019","article-title":"Health state values derived from people with multiple sclerosis for a condition-specific preference-based measure: multiple sclerosis Impact Scale-Eight Dimensions-Patient Version (MSIS-8D-P)","volume":"21","author":"Goodwin","year":"2018","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.jval.2025.09.3063_bib21","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s40273-021-01074-x","article-title":"Conceptualising \u2018benefits beyond health\u2019 in the context of the quality-adjusted life-year: a critical interpretive synthesis","volume":"39","author":"Engel","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"16","key":"10.1016\/j.jval.2025.09.3063_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16160","article-title":"Outcomes of social care for adults: developing a preference-weighted measure","volume":"16","author":"Netten","year":"2012","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1016\/j.jval.2025.09.3063_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hec.3014","article-title":"Scoring the ICECAP-A capability instrument. Estimation of a UK general population tariff","volume":"24","author":"Flynn","year":"2015","journal-title":"Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2025.09.3063_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1016652515418","article-title":"Health-related quality of life research and the capability approach of Amartya Sen","volume":"10","author":"Verkerk","year":"2001","journal-title":"Qual Life Res"},{"issue":"13-14","key":"10.1016\/j.jval.2025.09.3063_bib25","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3109\/09638288.2010.525287","article-title":"A review of the demographic, clinical and psychosocial correlates of perceived control in three chronic motor illnesses","volume":"33","author":"Eccles","year":"2011","journal-title":"Disabil Rehabil"},{"issue":"6","key":"10.1016\/j.jval.2025.09.3063_bib26","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1191\/1352458504ms1116rr","article-title":"Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review","volume":"10","author":"Gruenewald","year":"2004","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.jval.2025.09.3063_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1474-4422(05)70166-6","article-title":"Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing","volume":"4","author":"Mitchell","year":"2005","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jval.2025.09.3063_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1191\/1352458503ms871oa","article-title":"The use of quality of life measures in multiple sclerosis research","volume":"9","author":"Nortvedt","year":"2003","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.jval.2025.09.3063_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7224\/1537-2073.2018-087","article-title":"Effect of multiple sclerosis on daily activities, emotional well-being, and relationships: the global vsMS survey","volume":"22","author":"Bass","year":"2020","journal-title":"Int J MS Care"},{"issue":"1","key":"10.1016\/j.jval.2025.09.3063_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.60.1.31","article-title":"Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12)","volume":"60","author":"Hobart","year":"2003","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jval.2025.09.3063_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"10.1016\/j.jval.2025.09.3063_bib32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1191\/1352458502ms839oa","article-title":"Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters","volume":"8","author":"Flachenecker","year":"2002","journal-title":"Mult Scler"},{"key":"10.1016\/j.jval.2025.09.3063_bib33","article-title":"Identifying an important change estimate for the multiple sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results","volume":"1","author":"Mehta","year":"2015","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"13","key":"10.1016\/j.jval.2025.09.3063_bib34","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1177\/1352458513483890","article-title":"The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis","volume":"19","author":"Learmonth","year":"2013","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.jval.2025.09.3063_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40263-018-0586-5","article-title":"Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, phase III ENHANCE trial of prolonged-release fampridine","volume":"33","author":"Hobart","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jval.2025.09.3063_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.genhosppsych.2016.07.004","article-title":"Distribution-based estimates of minimal important difference for hospital anxiety and depression scale and impact of event scale-revised in survivors of acute respiratory failure","volume":"42","author":"Chan","year":"2016","journal-title":"Gen Hosp Psychiatry"},{"issue":"6","key":"10.1016\/j.jval.2025.09.3063_bib37","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1097\/HCR.0000000000000379","article-title":"Establishing the minimal clinically important difference for the Hospital Anxiety and Depression Scale in patients with cardiovascular disease","volume":"39","author":"Lemay","year":"2019","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"10.1016\/j.jval.2025.09.3063_bib38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1477-7525-6-46","article-title":"The minimal important difference of the Hospital Anxiety and Depression Scale in patients with chronic obstructive pulmonary disease","volume":"6","author":"Puhan","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"10.1016\/j.jval.2025.09.3063_bib39","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1185\/03007990902797675","article-title":"Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial","volume":"25","author":"Robinson","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2025.09.3063_bib40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.msard.2019.07.028","article-title":"Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis","volume":"35","author":"Rooney","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jval.2025.09.3063_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1472-6947-12-73","article-title":"The feasibility of collecting information from people with multiple sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MS","volume":"12","author":"Ford","year":"2012","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.jval.2025.09.3063_bib42","author":"Goodwin"},{"key":"10.1016\/j.jval.2025.09.3063_bib43","series-title":"Statistical Power Analysis for Behavioural Sciences","author":"Cohen","year":"1988"},{"issue":"4","key":"10.1016\/j.jval.2025.09.3063_bib44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1023499322593","article-title":"On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation","volume":"12","author":"Terwee","year":"2003","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.jval.2025.09.3063_bib45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0895-4356(99)00206-1","article-title":"Methods for assessing responsiveness: a critical review and recommendations","volume":"53","author":"Husted","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jval.2025.09.3063_bib46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40271-020-00461-4","article-title":"Involving patients in health economics research: \u201cThe PACTS Principles\u201d","volume":"14","author":"Hawton","year":"2021","journal-title":"Patient"},{"key":"10.1016\/j.jval.2025.09.3063_bib53","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1348\/014466501163904","article-title":"Brief report: Normative data for the HADS from a large non-clinical sample","volume":"40","author":"Crawford","year":"2001","journal-title":"British J Clin Psychol"},{"key":"10.1016\/j.jval.2025.09.3063_bib54","doi-asserted-by":"crossref","unstructured":"Janssen B., Szende A. Population Norms for the EQ-5D. 2013 Sep 26. In: Szende A., Janssen B., Cabases J., editors. Self-Reported Population Health: An International Perspective based on EQ-5D. Dordrecht, NL: Springer; 2014.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"10.1016\/j.jval.2025.09.3063_bib55","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12888-017-1211-8","article-title":"Assessing the validity of the ICECAP-A capability measure for adults with depression","volume":"17","author":"Mitchell","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jval.2025.09.3063_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114150","article-title":"What drives differences in preferences for health states between patients and the public? A qualitative investigation of respondents\u2019 thought processes","volume":"282","author":"Goodwin","year":"2021","journal-title":"Soc Sci Med"},{"issue":"2","key":"10.1016\/j.jval.2025.09.3063_bib48","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jval.2019.08.009","article-title":"What difference does it make? A comparison of health state preferences elicited from the general population and from people with multiple sclerosis","volume":"23","author":"Goodwin","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2025.09.3063_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.msard.2018.05.015","article-title":"Validating the portal population of the United Kingdom multiple sclerosis Register","volume":"24","author":"Middleton","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.jval.2025.09.3063_bib50","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.jval.2025.09.3063_bib51","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jval.2012.08.2201","article-title":"Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer","volume":"15","author":"Rowen","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2025.09.3063_bib52","first-page":"92","article-title":"Patient-reported outcome measures in multiple sclerosis","volume":"13","author":"Riazi","year":"2006","journal-title":"Int MS J"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525056207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525056207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:59:30Z","timestamp":1778086770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525056207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1098301525056207"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.09.3063","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Responsiveness of Preference-Based Health-Related Quality of Life, Social Care, and Well-Being Measures in the Context of Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.09.3063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}